Associated Papers
Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies.
Brlek P et al.
Cancers, 2025
PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.
Yang K et al.
Molecular Cancer, 2024
Chemoproteomics Reveals Glaucocalyxin A Induces Mitochondria-Dependent Apoptosis of Leukemia Cells via Covalently Binding to VDAC1.
An Y et al.
Advanced Biology, 2024
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition.
Gao C et al.
Frontiers in Pharmacology, 2023
Insights from γ-Secretase: Functional Genetics of Hidradenitis Suppurativa.
Vellaichamy G et al.
The Journal of Investigative Dermatology, 2021
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway.
Wei L et al.
Molecular Therapy Oncolytics, 2020
How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study.
Zhang H et al.
Journal of Biomolecular Structure & Dynamics, 2020
Pleckstrin homology domain of p210 BCR-ABL interacts with cardiolipin to regulate its mitochondrial translocation and subsequent mitophagy.
Shimasaki K et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms, 2018
Mutation Analysis in Chronic Myeloid Leukemia Patient in Chronic Phase on Imatinib Having Delayed Achievement of Milestones or Loss of Response.
Tripathi AK et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion, 2017
Integrating functional genomics to accelerate mechanistic personalized medicine.
Tyner JW
Cold Spring Harbor Molecular Case Studies, 2017
Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors.
Xu P et al.
Oncotargets and Therapy, 2017
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Okabe S et al.
Oncotarget, 2016
Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells.
Umezawa Y et al.
Oncotarget, 2016
Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study.
Ravichandran S et al.
Journal of Molecular Graphics & Modelling, 2015
In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs.
Xu HL et al.
Molecular Biosystems, 2014
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.
Janes MR et al.
Leukemia, 2013
Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.
Kurosu T et al.
Plos One, 2013
Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin.
Kajiguchi T et al.
European Journal of Haematology, 2012
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C et al.
Leukemia & Lymphoma, 2011
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.
Corrado C et al.
Cancer Letters, 2011
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
Fumagalli D et al.
Bmc Cancer, 2010
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.
Koldehoff M et al.
Haematologica, 2010
The role of tyrosine kinase inhibitors in tuberous sclerosis.
Koluman B et al.
British Journal of Haematology, 2009
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.
Zunder ER et al.
Cancer Cell, 2008
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
American Journal of Health-system Pharmacy : Ajhp : Official Journal of the American Society of Health-system Pharmacists, 2007
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
Prabhu S et al.
Oncogene, 2007
Resistance to targeted therapy in chronic myelogenous leukemia.
Hochhaus A et al.
Seminars in Hematology, 2007
Genomic approaches to lung cancer.
Thomas RK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Shah NP et al.
Cancer Cell, 2002